En-tête de navigationNavigation principaleSuiviFiche


Unité de recherche
PCRD EU
Numéro de projet
99.0471-6
Titre du projet
EUROVAC: European vaccine effort against HIV/AIDS (cluster proposal, 8-4)
Titre du projet anglais
EUROVAC: European vaccine effort against HIV/AIDS (cluster proposal, 8-4)

Textes relatifs à ce projet

 AllemandFrançaisItalienAnglais
Mots-clé
-
-
-
Anzeigen
Autre Numéro de projet
-
-
-
Anzeigen
Programme de recherche
-
-
-
Anzeigen
Description succincte
-
-
-
Anzeigen
Autres indications
-
-
-
Anzeigen
Partenaires et organisations internationales
-
-
-
Anzeigen
Résumé des résultats (Abstract)
-
-
-
Anzeigen
Références bases de données
-
-
-
Anzeigen

Textes saisis


CatégorieTexte
Mots-clé
(Anglais)
AIDS/HIV; vaccine; vaccinia; DNA; mucosal adjuvant;
Life Sciences; Medicine; Health; Safety; Scientific Research; Social Aspects
Autre Numéro de projet
(Anglais)
EU project number: QLK2-CT-1999-01321
Programme de recherche
(Anglais)
EU-programme: 5. Frame Research Programme - 1.1.2 Control of infectious diseases
Description succincte
(Anglais)
See abstract
Autres indications
(Anglais)
Full name of research-institution/enterprise:
Institut suisse de recherche expérimentale sur le cancer ISREC

Partenaires et organisations internationales
(Anglais)
Coordinator: CNRS, Lyon (F)
Résumé des résultats (Abstract)
(Anglais)
During the third year, four major projects were completed in Lausanne:
1/ We have established in mice that the recombinant modified Ankara vaccinia strains expressing the gag pol nef polygene administered by the nasal route is safe. A protocol to test safety of MVA/ NYVAC vaaccines adninistered by the nasal route has been accepted by the Delft ethical committee. The trial is starting on March 2003.
2/ Immunogenicity of recombinant NYVAC, MVA, SFV and DNA expressing clade B gag pol nef polygene was tested in HLA-A2 transgenic and C57BL/6 mice . All recombinant vaccines are immunogenic alone or in combination.
3/. A novel mucosal adjuvant, bacterial flagellin, has been shown to enhance both antibody and CTL production, to recruit antigen presenting cells into mucosal tissues and to modulate immune responses (Th2 polarization).
4/ Novel mucosal readouts have been developed to monitor CTL in vaginal tissues and are currently optimized and standardized.
Références bases de données
(Anglais)
Swiss Database: Euro-DB of the
State Secretariat for Education and Research
Hallwylstrasse 4
CH-3003 Berne, Switzerland
Tel. +41 31 322 74 82
Swiss Project-Number: 99.0471-6